Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 257

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 257
---
 |

Experienced and Proven Management Team. The combined company’s management team will combine expertise and experience in the discovery,
development, manufacturing and commercialization of biotechnology products. Over a twelve-month period prior to the entry of the Merger
Agreement, the FutureTech management team has had the opportunity to engage and evaluate the Longevity team. In addition, the entire senior
management team of Longevity is expected to continue with the company following the Business Combination to execute the business and strategic
growth plan; the combined company will be led by Bradford A. Zakes as its Chief Executive Officer, who has spent over thirty years in
various segments of the pharmaceutical, biotechnology and med-tech industries. Dr. Francesco Curra will serve as the Chief Technology
Officer and is a recognized medical ultrasound professional with approximately twenty years of academic and private sector R&D experience
in the fields of ultrasound imaging, high intensity focused ultrasound, nonlinear acoustics and tissue bioeffects.

Lock-Up.
The Longevity management and certain Longevity stockholders have agreed to a six-month lock-up period with respect to their shares of
combined company Common Stock, subject to customary exceptions which will provide important stability to combined company for a period
of time following the Business Combination;

Reasonableness of Merger Consideration. Following a review of the financial data provided to FutureTech, including the historical financial statements
of Longevity and the Targets and certain unaudited prospective financial information discussed in the section entitled “Shareholder
Proposal No. 1 — The Business Combination Proposal — Projected Financial Information” and FutureTech’s due diligence
review and financial and valuation analyses of Longevity, the FutureTech Board considered the transaction consideration to be issued to
Longevity’s equityholders and determined that the consideration was reasonable in light of such data and financial information.
Of note, the Merger Consideration represents a discount to the valuation range of (i) the equity value of $225.9 million obtained by comparing
the equity valuation of twelve comparable public companies in three different healthcare sub-verticals and (ii) the estimated $183.0 million
valuation implied by a discounted cash flow analysis performed by Newbridge. For more information, see “Proposal No. 1 — The
Business Combination Proposal — Opinion of Newbridge;”

| 130 |

Fairness Opinion. The FutureTech Board considered the opinion delivered by Newbridge to the effect that, as of the date of the opinion,
and subject to and based on the assumptions made, procedures followed